Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC)

Marksans Pharma Ltd. (NSE: MARKSANS; BSE:524404), one of the fastest-growing pharmaceutical companies in India, has announced that it has received final approval from the US Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC). The Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC) are bioequivalent to the reference listed drug (RLD), Mucinex Extended-Release Tablets, 600 mg and 1200 mg, of RB Health (US) LLC.

Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive. The company expects to launch the product immediately.

Commenting on the approval, Mark Saldanha, Managing Director of the Company said "We are delighted to announce the approval, which further strengthens our growing Cough and Cold OTC portfolio in the US. We are confident in tapping the market opportunity of the product and remain committed to working diligently towards sustaining this momentum in the coming quarters."

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 113.10 as compared to the previous close of Rs. 109.70. The total number of shares traded during the day was 356950 in over 4271 trades.

The stock hit an intraday high of Rs. 114.75 and intraday low of 110.00. The net turnover during the day was Rs. 40244563.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 USFDA FinalApproval ANDA